Kolexia
Pistilli Barbara Oncologie médicale
Pistilli Barbara
Oncologie médicale
Gustave-Roussy
Villejuif, France
386 Activités
640 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Fatigue Métastase tumorale Récidive tumorale locale Tumeurs du sein triple-négatives Tumeurs du cerveau Tumeurs du poumon Diarrhée Surpoids

Collaborateurs

Voir plus
Andre Fabrice
Andre Fabrice
Gustave-Roussy, Villejuif, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Cottu Paul-Henri
Cottu Paul-Henri
Clcc Institut Curie, Paris, France

Industries

Voir plus
Daiichi Sankyo
14 collaboration(s)
Dernière en 2023
Novartis
13 collaboration(s)
Dernière en 2023
AstraZeneca
8 collaboration(s)
Dernière en 2023
Pfizer
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Essai Clinique (Roche)   21 mars 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
ICARUSBREAST02: Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Essai Clinique (Daiichi Sankyo)   01 mars 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
ESMO open   12 février 2024
LESS: Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis
Essai Clinique (Agendia)   02 février 2024
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Essai Clinique (AstraZeneca)   24 janvier 2024
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
ESMO open   16 janvier 2024
Telehealth in breast cancer following the coronavirus disease 2019 pandemic.
Exploration of targeted anti-tumor therapy   26 décembre 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
Journal of the National Cancer Institute   07 décembre 2023